• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HEPARIN Drug Record

  • Summary
  • Interactions
  • Claims
  • HEPARIN chembl:CHEMBL1909300

    Alternate Names:

    HEPARIN
    HEPARINIC ACID
    CALCIPARINE
    HEPARIN SODIUM
    HEP-LOCK
    HEPARINATE
    LIQUAEMIN
    PANHEPRIN
    SODIUM HEPARIN
    chemidplus:9041-08-1
    chembl:CHEMBL1909300
    chemidplus:9005-49-6
    drugbank:01109
    pubchem.compound:22833565

    Drug Info:

    FDA Approval not approved
    Drug Indications for treatment of cystic fibrosis
    Drug Indications for treatment of pelvic pain of bladder origin and interstitital cystitis
    Drug Indications antithrombotic
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications anticoagulant
    Drug Class anticoagulants
    Year of Approval approved before 1982
    (1 More Sources)

    Publications:

    Chuang et al., 2001, Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin., J. Biol. Chem.
    Schedin-Weiss et al., 2010, Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes., Arch. Biochem. Biophys.
    Pappalardo et al., 2006, Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration., Perfusion
    Sun et al., 2007, A fluorescent polymeric heparin sensor., Chemistry
    Petitou et al., 1999, Synthesis of thrombin-inhibiting heparin mimetics without side effects., Nature
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Mirow et al., 2007, Plasma protein binding properties to immobilized heparin and heparin-albumin conjugate., Artif Organs
    Gettins et al., 2009, Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement., FEBS Lett.
    Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.
    Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy
    Berry et al., 2006, Heparin localization and fine structure regulate Burkitt's lymphoma growth., Biochem. Biophys. Res. Commun.
    Nisoli et al., 2000, Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion., Diabetes
    Miyata et al., 1995, Interaction between casein kinase II and the 90-kDa stress protein, HSP90., Biochemistry
    Patel et al., 2001, Chemokines have diverse abilities to form solid phase gradients., Clin. Immunol.
    Randi et al., 1992, Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin., J. Biol. Chem.
    Patey et al., 2006, Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases., J. Med. Chem.
    Rezaie, 2000, Heparin-binding exosite of factor Xa., Trends Cardiovasc. Med.
    Ignjatovic et al., 2007, Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?, Thromb. Res.
    Rosenberg, 1985, Role of heparin and heparinlike molecules in thrombosis and atherosclerosis., Fed. Proc.
    Van Iwaarden et al., 1994, Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides., Biochem. J.
    Fath et al., 1998, Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma., J. Biol. Chem.
    Walter et al., 1996, Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin., Arch. Biochem. Biophys.
    Hansen et al., 2000, Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin., Thromb. Res.
    Whinna et al., 1993, Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor., J. Protein Chem.
    Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature
    Harenberg et al., 1985, Anticoagulant and lipolytic effects of a low molecular weight heparin fraction., Thromb. Res.
    Eckel et al., 1988, Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation., Diabetes
    Hallgren et al., 2004, Histidines are critical for heparin-dependent activation of mast cell tryptase., J. Immunol.
    Bakillah et al., 1998, Lysine and arginine residues in the N-terminal 18% of apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein., Biochemistry
    Krul et al., 1988, Regional specificities of monoclonal anti-human apolipoprotein B antibodies., J. Lipid Res.
    Hansen et al., 1995, Identification of a homologous heparin binding peptide sequence present in fibronectin and the 70 kDa family of heat-shock proteins., Biochim. Biophys. Acta
    Wojtecka-Lukasik et al., 1984, Effects of neutral proteases from human leukocytes on plasma fibronectin., Thromb. Res.
    Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
    Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.
    Vettor et al., 2000, Substrate competition and insulin action in animal models., Int. J. Obes. Relat. Metab. Disord.
    Gambetti et al., 2005, Interaction with heparin protects tissue transglutaminase against inactivation by heating and by proteolysis., Biochimie
    Kolset et al., 1996, Serglycin-binding proteins in activated macrophages and platelets., J. Leukoc. Biol.
    Okano et al., 2001, Biochemical characterization of cholesterol-3-sulfate as the sole effector for the phosphorylation of HMG1 by casein kinase I in vitro., Biochem. Biophys. Res. Commun.
    Nakamura et al., 1995, Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery., J. Clin. Invest.
  • HEPARIN   SLPI

    Interaction Score: 6.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9593692 8615699


    Sources:
    NCI

  • HEPARIN   SRGN

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8613703


    Sources:
    NCI

  • HEPARIN   FGF4

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11486033


    Sources:
    NCI

  • HEPARIN   CCL21

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11286540


    Sources:
    NCI

  • HEPARIN   TFPI2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2416032


    Sources:
    NCI

  • HEPARIN   TPSB2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15265919


    Sources:
    NCI

  • HEPARIN   SDC1

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11333985


    Sources:
    NCI

  • HEPARIN   HLA-DRB3

    Interaction Score: 1.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28688202


    Sources:
    PharmGKB

  • HEPARIN   SERPINA5

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8136018


    Sources:
    NCI

  • HEPARIN   UCP2

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10868951


    Sources:
    NCI

  • HEPARIN   SERPINC1

    Interaction Score: 0.93

    Interaction Types & Directionality:
    activator (activating)
    potentiator

    Interaction Info:
    Trial Name heparin
    Novel drug target Established target
    Trial Name heparin, oral, liquid

    PMIDs:
    11278930 20816747 17201083 17600786 10201371 11752352 17537059 19818773


    Sources:
    TdgClinicalTrial TEND

  • HEPARIN   LIPC

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    4082106 3360217


    Sources:
    NCI

  • HEPARIN   PLA2G2A

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7883954


    Sources:
    NCI

  • HEPARIN   F10

    Interaction Score: 0.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name heparin
    Novel drug target Established target
    Trial Name heparin, oral, liquid

    PMIDs:
    17004727 11369259 17118432 3155697


    Sources:
    TdgClinicalTrial TEND

  • HEPARIN   SFTPA1

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7980398


    Sources:
    NCI

  • HEPARIN   NR5A1

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6372156


    Sources:
    NCI

  • HEPARIN   TFPI

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11150580


    Sources:
    NCI

  • HEPARIN   APOB

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9521691 2457642


    Sources:
    NCI

  • HEPARIN   VWF

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1400429


    Sources:
    NCI

  • HEPARIN   CSNK1A1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11243881


    Sources:
    NCI

  • HEPARIN   FCGR3B

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18492254


    Sources:
    NCI

  • HEPARIN   CSNK2A1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7794926


    Sources:
    NCI

  • HEPARIN   TGM2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15935280


    Sources:
    NCI

  • HEPARIN   FCGR3A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18492254


    Sources:
    NCI

  • HEPARIN   HPSE

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name M118
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • HEPARIN   F2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name octaparine, AVE-5026
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • HEPARIN   HSPA4

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7548155


    Sources:
    NCI

  • HEPARIN   SLC2A4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10997602


    Sources:
    NCI

  • HEPARIN   PIK3CG

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16904641


    Sources:
    NCI

  • TEND: HEPARIN

    • Version: 01-August-2011

    Alternate Names:
    HEPARIN Primary Drug Name

    Drug Info:
    Year of Approval approved before 1982
    Drug Class anticoagulants

    Publications:

  • TdgClinicalTrial: HEPARIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticoagulant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: HEPARIN

    • Version: 14-September-2017

    Alternate Names:
    C539 NCI drug code

    Drug Info:

    Publications:
    Sinosich et al., 1985, The influence of pergonal on in vitro production of placental protein 5 (PP5) by ovarian tumour cells., Tumour Biol.
    Park et al., 2001, Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence., Nature
    Bellosta et al., 2001, Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis., Mol. Cell. Biol.

  • PharmGKB: heparin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Karnes JH et al., 2017, Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)., Pharmacotherapy

  • ChemblDrugs: chembl:CHEMBL1909300

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21